CML-114: Interim Analysis from the OPTIC Trial - A Dose-Ranging Study of 3 Starting Doses of Ponatinib
Year: 2020
Type: conference-abstract
Authors: Jorge Cortes, Elza Lomaia, Anna Turkina, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Christine Rojas, Charles Chuah, Christopher Arthur, Jane Apperley, Dong-Wook Kim, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Michael Mauro, Jeffrey Lipton, Daniel Naranjo, Guohui Liu, Shouryadeep Srivastava, Michael Deininger
Institutions: Federal Almazov North-West Medical Research Centre, Hospital Ramos Mejía, Hospital del Salvador, Singapore General Hospital, Duke-NUS Medical School, Royal North Shore Hospital, Imperial College Healthcare NHS Trust, The Catholic University of Korea Seoul St. Mary's Hospital, Jena University Hospital, Université de Versailles Saint-Quentin-en-Yvelines, University of Bologna, Memorial Sloan Kettering Cancer Center, University of Toronto, Takeda Oncology (United States), University of Utah, Huntsman Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3105862600